Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 28

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 28
---
 requests. See “Special Meeting of the Shareholders”in the accompanying proxy statement/prospectus for a detailed description of the procedures to be followed if you wish to redeem your Public Shares for cash. Notwithstanding the foregoing, a holder of Public Shares, together with any affiliate of such Public Shareholder or any other person with whom such Public Shareholder is acting in concert or as a “group” (as defined in Section 13 of the Exchange Act), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 15% of the Public Shares, without our prior consent. Accordingly, if a Public Shareholder, alone or acting in concert as a group, seeks to redeem more than 15% of the Public Shares, then any such shares in excess of that 15% limitation would not be redeemed for cash, without our prior consent. The approval of each of the Business Combination Proposal and the Cayman Merger Proposal is a condition to the consummation of the Business Combination. The adoption of each of these proposal is conditioned on the approval of all of the Business Combination Proposal and the Cayman Merger Proposal. The Adjournment Proposal is not conditioned on the approval of any other proposal. If our shareholders do not approve each of the Condition Precedent Proposals, the Business Combination may not be consummated. Your attention is directed to the proxy statement/prospectus accompanying this notice (including the annexes thereto) for a more complete description of the proposed Business Combination and related transactions and each of the proposals. We urge you to read the accompanying proxy statement/prospectus carefully. If you have any questions or need assistance voting your APx ordinary shares, please contact, our proxy solicitor, by calling, or banks and brokers can call collect ator by emailing. This notice of Special Meeting and the proxy statement are available at.

|        |     | By Order of the Board of Directors, |
| , 2025 |     | Kyle Bransfield                     |
|        |     | Chief Executive Officer             |

TABLE OF CONTENTS

|                                                                                                    |     | Page |
| Frequently Used Terms                                                                              |     |  iii |
| Summary of the Proxy Statement/Prospectus                                                          |     |    1 |
| Selected Historical Financial Data of APx                                                          |     |   13 |
| Selected Historical Financial Data of OmnigenicsAI                                                 |     |   15 |
| Selected Unaudited Pro Forma Combined Financial Information                                        |     |   17